CD63 and breast carcinoma: To confirm if ITGAV could be released in tumour‐derived EVs, we analysed the colocalization of ITGAV and CD63 in tumours using a tissue array collected from 128 breast cancer patients at the Singapore National University Hospital (Table 5).